June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review concludes that finasteride and dutasteride are the most evidence-supported oral treatments for androgenetic alopecia, with dutasteride offering slightly greater hair count improvements and both affected by genetic response modifiers.
This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.
September 2022 in “Translational Andrology and Urology” This study found that in young men with post-finasteride syndrome, there are potential genetic risk factors associated with psychological and sexual dysfunctions, suggesting genetic screening may be beneficial before prescribing finasteride.
This review analyzed clinical trials and guidelines on 5-α-reductase inhibitors (5-ARIs) and found these drugs significantly improve urinary symptoms in BPH and stabilize hair loss in androgenic alopecia, but may cause sexual dysfunction and gynecomastia.
July 2025 in “Saudi Journal of Medicine and Public Health” In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.
